In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

The agency shared information from reports by users of compounded semaglutide and tirzepatide who have experienced health ...

One popular health platforms is promoting GLP-1 microdosing for weight loss: But how safe and effective is this approach?

A Cell Metabolism study reveals that GIPR signaling in oligodendrocytes enhances brain access and weight-loss efficacy of GLP ...

Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight, potentially transforming diabetes and obesity treatment.

Next-generation weight-loss pills could hit the market in the coming months, with new data raising a key question: Will ...

New studies found that Americans with type 2 diabetes who are taking GLP-1 drugs like Ozempic and Mounjaro could face an ...

These weight loss injections, GLP-1s like Wegovy, (same drug as Ozempic), and Zepbound (same drug as Mounjaro), are offering hope to millions, raising concerns for others, and creating insurance ...

GLP-1 medications have an impressive history of weight loss, but there are options to consider. For example, one study on the oral medication Qsymia found people lost up to 11% of their body ...